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Abstract The sequencing of the human genome is now
well recognized as the starting point of personalized
medicine. Nonetheless, everyone is unique and can develop
different phenotypes of the same disease, despite identical
genotypes, as well illustrated by discordant monozygotic
twins. To recognize these differences, one of the easiest
and most familiar examples of biomarkers capable of
identifying and predicting the outcome of patients is rep-
resented by serum autoantibodies. In this review, we will
describe the concept of personalized medicine and discuss
the predictive, prognostic and preventive role of antinu-
clear antibodies (ANA), anti-citrullinated peptide antibod-
ies (ACPA), rare autoantibodies and anti-drug antibodies
(ADA), to evaluate how these can help to identify different
disease immune phenotypes and to choose the best option
for treating and monitoring rheumatic patients in everyday
practice. The importance of ANA resides in the prediction
of clinical manifestations in systemic sclerosis and sys-
temic lupus erythematosus and their association with
malignancies. ACPA have a predictive role in rheumatoid
arthritis, they are associated with the development of a
more aggressive disease, extra-articular manifestations and
premature mortality in RA patients; moreover, they are
capable of predicting therapeutic response. Rare autoanti-
bodies are associated with different disease manifestations
and also with a greater incidence of cancer. The determi-
nation of ADA levels may be useful in patients where the
clinical efficacy of TNF-a inhibitor has dropped, for the
assessment of a right management. The resulting scenario
supports serum autoantibodies as the cornerstone of per-
sonalized medicine in autoimmune diseases.
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Introduction
Following the path of holistic medicine, on the footsteps of
Hippocrates, who encouraged his disciples to focus their
attention more on ‘‘what kind of person has a disease than
to know what kind of disease a person has’’ [1], the human
being has reached the goal of a molecular knowledge of
itself, revealing the secrets of the genome, through the
Human Genome Project completed in 2003. The last dec-
ades have seen enormous advances in proteomics, meta-
bolomics and genomics, but the path to the summit is still
long [2], as well illustrated by the complexity of the
microbiome [3].
From the current stratified medicine, which identifies a
group of patients who can benefit from a treatment, med-
icine is moving toward a personalized approach, whose
goal is the right therapy for the right patient at the right
time: in other words, a medicine that takes into account
individual variability to realize the best preventive and
therapeutic strategies [4]. Therapeutic resources for
rheumatologic disorders have had a significant develop-
ment with the advent of biotechnological therapies which
have radically changed the course of the disease, the
prognosis and the patient’s quality of life. These concepts
require a personalized approach based on the risk
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stratification and on the genetic background of the patient,
as well illustrated by Talamonti and colleagues in the case
of HLA-Cw06 to predict the response to ustekinumab [5].
Despite these improvements, not all autoimmune diseases
respond adequately to therapeutic agents nor we can pre-
dict which patients are more susceptible; therefore, it is
important to focus on specific preventive measures to
identify the ones at risk of developing autoimmune dis-
eases and those who may lead to more severe
manifestations.
To realize the purpose of personalized medicine in
rheumatology, one of the most useful examples of
biomarkers capable of identifying and predicting the out-
come of patients, to set appropriate preventative measures,
is representing by serum autoantibodies.
Personalized medicine
Personalized medicine is a system that integrates molecular
and biochemical characteristics with patient clinical data,
thus introducing the possibility of predicting the disease
before the onset of clinical signs and symptoms. It also
offers the opportunity to focus on prevention and early
intervention, rather than treating advanced stages of dis-
eases and their complications. In this perspective, medical
care has to be tailored for each individual, with the aim of
offering the best available care for each patient [6, 7].
This approach is part of the ‘‘P4’’ medicine, which not
only recognizes the personalized nature of modern medi-
cine, but also expands its horizon to its predictive, pre-
ventive and participatory identity [8]. There are numerous
advantages in personalizing our medical approach to
patients rather than disease, and one of these is the first
‘‘P’’, that is, prediction. Personalized medicine is expected
to subdivide patients into high- and low-risk tiers, based on
the integration between genetic factors and biomarkers that
provide information on the severity and progression of the
diseases [9, 10]. These aspects need to be combined with
other factors to increase their predictive value; these
include lifestyle (i.e., smoking, obesity), family history for
autoimmune disease, genetic profile, clinical manifestation
and other laboratory parameters; all of these should be
considered as a potential target for prevention and delaying
the onset and progression of disease, possibly mediated by
additional mechanisms such as the microbiome or epige-
netic changes [9, 11]. In this scenario, serum autoanti-
bodies are potentially helpful markers to recognize variants
of the same syndrome, enabling to subdivide patients into
categories to predict the course of the disease and the
possible response to treatment. By excluding patients for
whom diagnostic and therapeutic measures are unneces-
sary, superfluous waste of resources is prevented, resulting
in benefits both for the patient and the health-care system
[6, 12].
The second ‘‘P’’ stands for prevention, whose purpose
is to identify at-risk individuals before the development
of clinical manifestations, to implement preventive
measures [13]. Traditionally, therapeutic decisions were
taken on the basis of physical signs and symptoms
observed during medical examination, but frequently
these features failed to fully describe diseases. In fact,
these signs are often non-specific and subjective; they
are also often blurred or absent at the initial stages. So,
this approach may miss the opportunity for prevention
and early intervention, which is fundamental for the
outcome of the patient [6]. Different from this approach,
the purpose of personalized medicine is to use
biomarkers as screening to identify subjects at high risk
of developing disease. This can lead to clinical and
economic benefits that come from the prevention of late
diagnosis and treatment of complications, resulting in
reduced hospitalization for adverse drug reactions and
less unnecessary diagnostic interventions. It is not to be
underestimated, however, that with the improvement of
the quality of life, patients are less likely to use drugs
and they would address less frequently to the clinician
[9, 12].
The third ‘‘P’’ is to personalize. ‘‘Happy families are all
alike; every unhappy family is unhappy in its own way’’;
paraphrasing this Tolstoy’s quote, when people have a
problem, they feel different from the others and feel that
they do not belong to the average cohort. As a matter of
fact, that is not only a subjective perception, but indeed
every individual, like the same diseases, are unique, from
the genome to environmental factors [14]. In addition, the
interpersonal diversity influences the therapeutic response
[13]. This variability is elegantly illustrated by monozy-
gotic twins that are largely discordant for autoimmune and
chronic inflammatory conditions, thus possibly underlining
the effects of non-hereditary factors [15]; hence, each
person must be treated as a unique individual [16]. Based
on this assumption, pharmaceutical research is shifting
from mass therapies to targeted therapies, according to
biomarkers that identify those patients who are more likely
to successfully respond to treatments [17].
Finally, the fourth ‘‘P’’ indicates the participatory role of
personalized medicine; the individual must be involved in
the preventive process and personalized treatment to be
successful [18]. This main role covered by the individual
enriches the model of patient-centered medicine.
We should be aware that autoantibodies represent only a
piece (with reasonable costs and within reach for all clin-
ical settings) of a larger scenario and it is obviously unli-
kely that they are sufficient to achieve personalized
medicine.
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The ABC of serum autoantibodies
Autoimmune diseases are estimated to affect nearly 5% of
the US population [19] and in the vast majority of cases
these are characterized by serum autoantibodies which
represent diagnostic markers with, in some cases, a prog-
nostic value and thus in agreement with a personalized
management [11, 20], as in the case of paraneoplastic
autoimmunity [11]. In general terms, the autoantibody
development more frequently precedes the clinical onset of
disease [11, 20, 21]. Specific antibody profiles can lead to
the identification of disease sub-phenotypes, but only in a
few cases the antibody titer correlates with the severity of
clinical manifestations or the response to treatment.
Therefore, autoantibodies may help the clinician in deter-
mining the follow-up and in choosing an appropriate
therapy, but might be ineffective in disease severity mon-
itoring [11, 20, 21].
The inconvenient truth of autoantibodies is that these are
also detected in a substantial percentage of healthy sub-
jects; thus, their isolated finding has a low positive pre-
dictive value which needs to be integrated with other
laboratory parameters and patient risk factors [22]. So, it is
true that early diagnosis can reduce the economic burden of
health care, but the interpretation of serum autoantibodies
must be done with proper judgment to avoid inappropriate
diagnosis and superfluous treatments. Instead, in subjects
with high pre-test probability of an autoimmune disease,
the autoantibody positivity is sufficient to set preventative
measures such as the elimination of modifiable proposed or
established risk factors (smoking, obesity and UV exposure
among others) [11] and to warrant a regular rheumatolog-
ical follow-up.
Antinuclear antibodies (ANA)
ANA are the most frequently (and often inappropriately)
prescribed autoantibody test and they are virtually always
positive in connective tissue diseases, i.e., systemic lupus
erythematosus (SLE), Sjo¨gren’s syndrome (SjS), sclero-
derma (SSc), polymyositis and dermatomyositis (PM/DM).
The ANA interpretation must thus be driven by clinical
suspicion, but their interpretation also depends on both titer
and pattern. Different staining patterns, classified into three
major groups, nuclear, cytoplasmic and mitotic, give
indication on the significance of ANA and type of rheu-
matic disease (Table 1), and the recent work from the
autoantibody standardization group (http://www.ANApat
terns.org) provided a long overdue description of the pos-
sible profiles. In fact, the gold standard for detecting ANA
remains indirect immunofluorescence test (IIF) on HEp-2
cells; however, IIF is time consuming and requires skilled
operators to avoid variability. So, new ANA testing
strategies have emerged in the last decades, particularly in
terms of automation and multiplex analyses. The expected
advantages of automated IIF are the reduction of false-
negative and false-positive results, the improvement of the
uniformity between different readers and laboratories and
the efficiency of the evaluation procedure [23]; but unfor-
tunately the sensitivity for rare patterns is not yet adequate
and can lead to false-negative results [24, 25].
It is still unclear what significance ANA may have in
asymptomatic patients, since they are not specific markers
of connective tissue diseases and can be falsely positive
in healthy subjects (the prevalence of ANA in the general
population is 13.8%) [26], especially in seniors, as well as
in patients with other chronic inflammatory or infectious
diseases; otherwise, they can precede clinical manifesta-
tions and diagnosis in SSc [27] and SLE [28]. The current
recommendations state that ANA-positive subjects should
be tested for antibodies to extractable nuclear antigens
(anti-ENA) and anti-double-stranded DNA antibodies
(anti-dsDNA) [29, 30]. The presence of multiple anti-
bodies thus becomes specific for systemic rheumatic dis-
order and helps the diagnostic process. To improve the
appropriateness of the immunological diagnosis of sys-
temic autoimmune diseases, to accelerate time for com-
pleting diagnostic process and to avoid waste of money,
the introduction of ANA reflex test has been proposed
[31]. The diagnostic algorithm suggested by Tonutti and
colleagues begins with a first-line high sensitivity test
(i.e., ANA IIF on HEp-2 cells) to allow antibody posi-
tivity recognition and the definition of pattern and titer.
The second-line tests (high specificity) are done for ANA
titers C1:160 and include, as mentioned, anti-dsDNA and
anti-ENA (by ELISA) to evaluate specific antigenic
expression. Figure 1 shows the second-line tests based on
the ANA patterns found in IIF.
The predictive significance of ANA has been clearly
demonstrated in the seminal work by Arbuckle and col-
leagues [28]. They studied 130 patients with SLE, whose
serum had been collected many years before the diagnosis.
Most patients harbored at least one autoantibody up to
9 years before the development of clinical manifestations
and therefore diagnosis of SLE, in particular ANA and also
antiphospholipid, anti-Ro and anti-La antibodies [32]. The
mean time to diagnosis for these autoantibodies was about
3.4 years, while for anti-double-stranded DNA autoanti-
bodies 2.2 years. Later predictors of disease were anti-Sm
and anti-nuclear ribonucleoprotein antibodies, which ten-
ded to coincide with the onset of signs and symptoms.
Another interesting observation is that new types of
autoantibodies gradually accumulated before the diagnosis
and reached a plateau at the diagnosis. Considering that
while ANA, anti-Ro, anti-La and anti-phospholipid
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Table 1 IIF ANA patterns and relevant clinical associations
Pattern Related antigens Related diagnosis
Nuclear
Homogeneous dsDNA, histones, nucleosomes SLE, drug-induced lupus, JIA
Speckled hnRNP, U1RNP, Sm, SS-A, SS-B, RNAP-III, Mi-2, Ku MCTD, SLE, SjS, DM, SSc/PM overlap
Dense fine speckled DFS70/LEDGF Rare in SLE, SjS, SSc
Fine speckled SS-A, SS-B, Mi-2, TIF1c, TIF1b, Ku, RNA helicase A,
replication protein A
SjS, SLE, DM, SSc/PM overlap
Large/coarse speckled hnRNP, U1RNP, Sm, RNAP-III MCTD, SLE, SSc
Centromere CENP-A/B lcSSc, PBC
Discrete nuclear dots
Multiple nuclear dots Sp100, PML protein, MJ/NXP-2 PBC, SARD, PM/DM
Few nuclear dots p80-coilin, SMN SjS, SLE, SSc, PM, asymptomatic subjects
Nucleolar
Homogeneous PM/Scl75, PM/Scl100, Th/To, B23 nucleophosmin,
nucleolin, No55/SC65
SSc, SSc/PM overlap
Clumpy U3-snoRNP/fibrillarin SSc
Punctate RNAP-I, hUBF/NOR-90 SSc, SjS
Nuclear envelope (NE)
Smooth NE Lamins A, B, C, or lamin associated proteins SLE, SjS, seronegative arthritis
Punctate NE Nuclear pore complex proteins PBC
Pleomorphic
PCNA-like PCNA SLE, other conditions
CENP F-like CENP-F Cancer, other conditions
Cytoplasmic
Fibrillar
Linear/actin Actin, non-muscle myosin MCTD, CH, cirrhosis, MG, CD, PBC, long-term HD
Filamentous/
microtubules
Vimentin, cytokeratin Infections or inflammations, long-term HD, ALD, SARD,
PsO, healthy subjects
Segmental a actinin, vinculin, tropomyosin MG, CD, UC
Speckled
Discrete dots GW182, Su/Ago2, Ge-1 PBC, SARD, neurological and autoimmune conditions
Dense fine speckled PL-7, PL-12, ribosomal P proteins ASS, PM/DM, SLE, juvenile SLE, neuroSLE
Fine speckled Jo1/histidyl-tRNA synthetase ASS, PM/DM, lcSSc, IPE
Reticular/AMA PDC-E2/M2, BCOADC-E2, OGDC-E2, E1a subunit of
PDC, E3BP/proteinX
PBC, SSc, rare in other SARD
Polar/Golgi-like Giantin/macrogolgin, golgin-95/GM130, golgin-160, golgin-
97, golgin-245
Rare in SjS, SLE, RA, MCTD, GPA, ICA, PCD, viral
infections
Rods and rings IMPDH2, others HCV patients post IFN/ribavirin, rare in SLE,
Hashimoto’s and healthy controls
Mitotic
Centrosome Pericentrin, ninein, Cep250, Cep110, enolase Rare in SSc, RD, infections (viral and mycoplasma)
Spindle fibers HsEg5 Rare in SjS, SLE, other SARD
NuMA-like Centrophilin SjS, SLE, other
Intercellular bridge Aurora kinase B, CENP-E, MSA2, KIF14, MKLP1 Rare in SSc, RD, malignancies
Mitotic chromosomal
envelope
Modified histone H3, MCA1 Rare in DLE, CLL, SjS, PMR
Table 1 illustrates ANA patterns in IIF in three major categories, subdivided into groups and subgroups of patterns, with their antigenic and
diagnostic associations. The information was taken from http://www.ANApattern.org and the related diagnoses were added by Chan EKL et al.
[84]
SLE systemic lupus erythematosus, JIA juvenile idiopathic arthritis, MCTD mixed connective tissue disease, SjS Sjo¨gren’s syndrome, DM
dermatomyositis, PM polymyositis, SSc systemic sclerosis (lc limited, dc diffuse), PBC primary biliary cholangitis, SARD systemic autoimmune
rheumatic diseases, CH chronic hepatitis, MG myasthenia gravis, CD Crohn’s disease, HD haemodialysis, ALD alcoholic liver disease, PsO
psoriasis, UC ulcerative colitis, ASS anti-synthetase syndrome, IPE idiopathic pleural effusion, RA rheumatoid arthritis, GPA granulomatosis
with polyangiitis, ICA idiopathic cerebellar ataxia, PCD paraneoplastic cerebellar degeneration, RD Raynaud’s phenomenon, DLE discoid lupus
erythematosus, CLL chronic lymphocytic leukaemia, PMR polymyalgia rheumatica
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antibodies may also be present in healthy subjects, anti-
dsDNA, anti-Sm and anti-nuclear ribonucleoprotein anti-
bodies are very rare in the general population. Accordingly,
the positivity of these aforementioned autoantibodies
should lead to close monitoring.
The value of ANA is not limited to diagnosis, but may
have a prognostic role in specific clinical settings such as
SSc, where the nucleolar pattern has been associated with a
more rapid progression to late scleroderma pattern at
nailfold capillaroscopy [33]. Moreover, the presence of
abnormal nailfold capillaries with ANA positivity is asso-
ciated with an increase of mortality in patients with Ray-
naud’s phenomenon without previously known connective
tissue disease exclusively in women [34]. The ANA
prognostic value is also reported in juvenile idiopathic
arthritis, being associated with the predisposition to uveitis
[35].
Finally, ANA and anti-ENA, in particular anti-Scl-70
antibodies, may be associated with malignancies, espe-
cially in patients with SSc and inflammatory myositis [36].
Another correlation has been reported with lymphomas, as
serum ANA were significantly higher in patients with
disease than in controls. In addition, it has been found that
the level of lactate dehydrogenase in ANA-positive
patients was lower, thus suggesting that these patients have
a better prognosis than ANA-negative patients, probably
demonstrating the existence of an anti-tumor response that
can be associated with a better prognosis [37].
Anti-citrullinated peptide antibodies (ACPA)
ACPA, together with rheumatoid factor (RF), are the
characteristic antibodies of rheumatoid arthritis (RA),
manifesting higher specificity and lower sensitivity com-
pared to RF for RA. ACPA can divide patients with RA
into two subgroups that differ in prognosis and response to
treatment [38, 39] (Fig. 2). Patients with ACPA-positive
RA differ from seronegative ones in genetics and envi-
ronmental risk factors. The presence of ACPA is associated
with genetic interaction between HLA-DRB1 shared epi-
tope (SE) and PTPN22 risk allele [40], and this points out
how MHC class II-dependent T cell activation plays a
central pathogenic role in the development of ACPA-pos-
itive RA. Furthermore, other gene interactions associated
with ACPA-positive RA have been confirmed in several
studies [4, 38]. ACPA are highly prevalent not only in
patients with HLA-DRB1 SE, but also in those with HLA-
DRB1*15 non-SE, proposing that this latter allele can act
as a second trigger that may intensify autoimmune
response in predisposed subjects [41]. Even gene–envi-
ronment interaction can determine ACPA-positive RA,
particularly in association with smoking and HLA-DRB1
SE, or with smoking and PTPN22 [38]. It is interesting to
note that SE and smoking are associated with the presence
of all three autoantibodies specifically related with RA
[ACPA, RF and anti-carbamylated protein antibodies (anti-
CarP)] [42].
The influence of environmental factors, particularly
smoking, has been shown to be a risk factor for the
development of ACPA-positive RA; other environmental
risk factors associated with ACPA are excessive coffee
consumption, use of oral contraceptives and periodontitis
1Possibily including anti-RNA polymerase III.  
2Possibily including anti-PM/Scl. 
3Including anti t-RNA synthetases and anti-P ribosomal. 
ANA IIF
Nuclear 
homogeneous
≥ 1:160
Anti-ENA
Anti-ds DNA
Nuclear speckled 
≥ 1:160
Anti-ENA1
Anti-ds DNA
Nuclear Scl70 like
≥ 1:160
Anti-ENA2
Citoplasmic 
speckled
≥ 1:160 
Anti-ENA3
Pleomorphic 
PCNA like (any 
titre)
Anti-PCNA
Centromere
No confirmation 
if high titres
In uncertain case 
antiCENP B
Fig. 1 ANA reflex test, modified from Tonutti et al. [31]
ACPA 
positive 
RA
Genetic and enviromental 
determinants: 
- HLA alleles
- PTPN22 risk allele
- Smoking exposure
Clinical features:
- Joint destruction 
(severe disease)
- Extra-articular 
manifestations (nodules, 
vasculitis, pleuritis) Response to therapies:
- Rituximab: good 
response
- Abatacept: good 
response
- Anti-TNF: variable 
response
Fig. 2 Features of ACPA-positive RA. Modified from Malmstrom
et al. [39, 104–114]
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caused by Porphyromonas gingivalis, while moderate
alcohol consumption may be protective against this RA
subtype [43, 44].
As previously discussed for ANA, also ACPA has a
predictive role in autoimmune diseases, as well as RF and
anti-RA-33 autoantibodies. In fact, they may occur early in
the course of RA and are often present several years before
the first symptoms [45, 46].
Numerous studies have shown that the presence of
ACPA and their concentration are associated with the
development of a more aggressive disease. Positive serum
ACPA at baseline leads to a progressing and destructive
form of RA, and they are the strongest independent pre-
dictor of radiographic damage [47–49]. ACPA have also
been correlated with increased inflammation and extra-ar-
ticular manifestations, high rates of disability and cardio-
vascular disease, with the latter most responsible for the
premature mortality in RA [38].
The distinction between ACPA-positive and ACPA-
negative patients can also help us in the therapeutic choice;
in fact, the superior efficacy of agents such as rituximab
and abatacept in ACPA-positive patients has been
demonstrated [50, 51]. This can occur because in these
patients, the contribution of B cells to RA pathogenesis is
more pronounced, and they might be more responsive to B
cell-directed treatments than other patients [52]. Also,
methotrexate seems to be more effective in ACPA-positive
subjects, in those patients in whom the arthritis stage is not
fully defined by the ACR criteria, and it may delay the
onset of RA [38]. Conversely, ACPA positivity is corre-
lated with a reduced response to all anti-tumor necrosis
factor biologics [53].
Rare autoantibodies
Rare autoantibodies characterize nearly all rheumatic dis-
eases, despite not being included in any classification
criteria set. Due to their low penetrance, they are not used
as first-line test or generally available in routine laboratory,
but they may help the clinician in making more accurate
diagnoses and better management of patients, because they
are associated with different disease manifestations and
also with a greater incidence of cancer [54]. This is par-
ticularly relevant for SSc, inflammatory myositis and SLE,
for which we should note that the proposed clinical sig-
nificance is derived from small cross-sectional studies.
The most significant autoantibodies in SSc are anti-
centromere, anti-RNA polymerase III (anti-RNAP) and
anti-Scl70, while anti-U3RNP is rarely found. Other
autoantibodies are listed in Table 2 with their proposed
clinical associations. Anti-RNAP antibodies are related to
diffuse cutaneous SSc [55], and they are the most consis-
tent predictors of scleroderma renal crisis [55]. It has also
been shown that patients with anti-RNAP antibodies pre-
sent more solid tumors and that these are temporally
associated with the onset of SSc [36, 56]. Anti-Scl-70
antibodies are associated with a higher skin score, disease
severity and activity [57], and they are also strong pre-
dictors of the development of pulmonary fibrosis [58, 59],
digital ulcers [60] and malignancies [61]. Finally, anti-
U3RNP antibodies are strongly associated with muscle
involvement and with an increased risk of pulmonary
arterial hypertension [59, 62, 63].
In the case of PM/DM, serum autoantibodies can be
divided into myositis-specific antibodies (MSAs) (anti-Jo1,
anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-Mi-2, anti-
SRP, anti-KS, anti-TIF1c/a (anti-155/140), anti-TIF1b,
anti-MJ/NXP-2, anti-MDA5/CADM-140, anti-SAE) and
myositis-associated antibodies (MAAs) (anti-PM-Scl, anti-
Ku, anti-U1-RNP, anti-U1/U2-RNP, anti-U3-RNP) [64].
The most noteworthy clinical associations are reported
below, while others are reported in Table 3. In general
terms, rare autoantibodies in myositis are used to predict
more severe forms, including those associated with cancer
Table 2 Rare autoantibodies in systemic sclerosis and reported clinical associations
Autoantibody Prevalence (%) Clinical associations References
Anti-RNAP 6–31 dcSSc, renal crisis, malignancies [85, 86]
Anti-Scl70 10–40 dcSSc, ILD, digital ulcers, cardiac involvement, malignancies [87, 88]
Anti-U3RNP 5–8 dcSSc, cardiomyopathy, myopathy, PAH, ILD, severe small bowel involvement [89]
Anti-U1RNP 4–14 lcSSc, PAH, overlap syndrome [90]
Anti-Ku 1–3 Muscle and joint involvement [91]
Anti-PM-Scl 2–10 myositis, arthritis, lung or kidney involvement and mechanic’s hands [92]
Anti-Th/To 1–10 lcSSc, PAH, ILD, puffy fingers, small bowel disease, hypothyroidism [93]
Anti-U11/U12RNP 3 ILD [94]
dcSSc diffuse systemic sclerosis, lcSSc limited systemic sclerosis, PAH pulmonary arterial hypertension, PBC primary biliary cholangitis, ILD
interstitial lung disease
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as many studies support the possibility that DM and PM are
paraneoplastic, particularly DM [65]. Some autoantibodies
are associated with major recurrence of neoplasms, and
these are anti-TIF1c/a (anti-155-140) and anti NXP2
antibodies [66, 67]. Jo-1 and other anti-aminoacyl tRNA
synthetases (anti-ARS) antibodies (PL-7, PL-12, EJ, OJ,
KS) are associated with the so-called anti-synthetase syn-
drome, characterized by myositis, interstitial lung disease,
arthritis, mechanic’s hands and Raynaud’s phenomenon
[68, 69]. Anti-Mi-2 antibodies are related to DM with its
typical skin manifestation, to good steroid response and
good prognosis [70]. Anti-SRP is specific for PM and
correlates with a form of necrotizing myopathy, associated
with a worse therapeutic response and poor prognosis
[64, 71]. Rare autoantibodies detectable in SLE are listed in
Table 4; among these, anti-Sm antibodies are associated
with lupus nephritis and neuropsychiatric complications,
and renal disease association is stronger when they are
found together with anti-dsDNA [72]. These antibodies are
also associated with discoid lupus and photosensitivity
[73]. Anti-ribosomal P antibodies are detected in the
cerebrospinal fluid of patients with neuropsychiatric SLE
[74], indicating blood–brain barrier permeation, while they
are also related to renal [75] and hepatic damages [76],
malar rash, oral ulcers and photosensitivity [77].
Anti-drug antibodies (ADA)
Since the introduction of biological drugs, the treatment of
immune-mediated inflammatory diseases has witnessed an
enormous improvement in the clinical armamentarium.
Indeed, tumor necrosis factor a (TNF-a) inhibitors neu-
tralizes the cytokine pro-inflammatory effect. Infliximab
(IFX), adalimumab (ADL), golimumab (GOL), etanercept
(ETA) and certolizumab (CTZ) can induce an immune
response with the formation of autoantibodies against the
drug, i.e., elicit immunogenicity, particularly after their
prolonged use [78, 79].
ADA formation is caused by the recognition of drugs as
non-self substances by the immune system. ADA ulti-
mately act by causing the formation of complexes that
block the binding between the drug and the target and also
Table 3 Rare autoantibodies in myositis and reported clinical associations. Modified from Satoh et al. [64]
Autoantibody Prevalence (%) Clinical associations References
Anti-ARS 1–30 Anti-synthetase syndrome [69, 95]
Anti-Mi2 10 DM with typical skin lesions, mild disease [69, 70, 95]
Anti-TIF1c 10–15 Severe DM, malignancies [70, 95]
Anti-NPX2 1–5 Severe DM, severe skin disease, malignancies [69, 70, 95]
Anti-MDA5 15–20 CADM, ILD, severe skin manifestations, poor prognosis [69, 95, 96]
Anti-SAE 1 Amyopathic DM [95]
Anti-SRP 5 Necrotizing myopathy [70]
Anti-HMGCR 6 Necrotizing myopathy, proximal muscle weakness, elevated CK levels, prior statin use [70, 95, 97]
Anti-ARS anti-aminoacyl tRNA synthetases (Jo1, PL-7, PL-12, EJ, OJ, KS), DM dermatomyositis, CADM clinically amyopathic dermato-
myositis, ILD interstitial lung disease, CK creatine kinase
Table 4 Rare autoantibodies in systemic lupus erythematosus and reported associations
Autoantibody Prevalence
(%)
Clinical associations References
Anti-Sm 15 LN, NPSLE, discoid SLE, photosensitivity [98, 99]
Anti-
ribosomal P
10 NPSLE, renal and hepatic disorders, malar rash, oral ulcer and photosensitivity, blood–brain barrier
permeation
[77, 98]
Anti-La (SS-
B)
10–15 Organ dysfunction (kidney, lung, liver) [100, 101]
Anti-Ki 6–20 Hashimoto’s thyroiditis, ITP, idiopathic ILD, PM/SSc overlap, synovitis, pericarditis, PAH, skin
involvement and sicca symptoms
[102]
Anti-histone 21–81 Drug-induced SLE [103]
LN lupus nephritis, NPSLE neuro psychiatric SLE, SCLE subacute cutaneous SLE, UCTD undifferentiated connective tissue disease, ITP
autoimmune thrombocytopenia
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enhance the drug’s clearance [78]. Antibodies thus lead to
a reduction in the serum levels of the drug to sub-thera-
peutic levels, resulting in loss of clinical efficacy [79].
Therapeutic drug monitoring, done by measuring the
TNF-a inhibitors serum levels and ADA, is considered an
important factor for personalized TNF-a inhibitor treat-
ment in chronic autoimmune diseases [80]. Nevertheless,
the mere presence of ADA does not directly correlate to
drug loss of response and clinical consequences, since a
significant amount of ADA is needed to neutralize much of
the serum drug, which is usually given in high doses. More
importantly, there is no agreement on the laboratory
methods to be used for ADA detection in clinical practice.
The significance of ADA largely depends on the quantity
of antibodies produced and on the amount of drug not
bound to them; if the quantity of ADA-free drug is sub-
stantial, the clinical impact will be minimal [81]. Several
studies have shown that ADA become detectable especially
within the first year of treatment with TNF-a inhibitors,
while their immunogenicity is very low after the first year
of therapy [82, 83]. ADA levels are diminished using
maintenance therapy rather than episodic therapy, since
prolonged periods in which the drug is sub-dosed are
avoided [80]. Moreover, patients treated concomitantly
with MTX have a lower risk of developing such antibodies,
similarly to those responding to therapy [78]. Overall, the
determination of ADA levels and anti-TNF-a drug may be
useful in patients where the clinical efficacy of TNF-a
inhibitor has dropped. Pecoraro and colleagues suggest that
in the presence of high ADA levels, either with optimal or
suboptimal drug levels, the anti-TNF-a should be changed,
while, in the case of low ADA levels, if drug levels are not
adequate, the dosage or frequency of drug administration
should be increased. Ultimately, however, the secondary
loss of efficacy of an anti-TNF-a drug will lead to a
treatment switch regardless of the mechanisms responsible
for such loss. However others, in particular Steenholdt,
suggest a different approach as shown in Fig. 3.
Conclusions
The technological advances and a thorough knowledge of
diseases pathogenesis over the last decade, combined with
the increasing expectations of patients, have laid the
foundation for developing an individualized management
for a single patient, as opposed to that from the ‘one size
fits all’ older school approach. The benefits of this
approach have been discussed here, but they underline the
numerous unmet needs in this field. In the case of serum
autoantibodies, we cannot overlook the technological and
methodological limitations that preclude (or prevent from)
conclusive evidence. We would need more sensitive
methods and experienced operators for the identification of
rare antibodies and patterns. Moreover, most hospitals do
not have laboratories with adequate machinery for rare
autoantibodies or lack adequate standardization.
In general terms, the information derived from antibody
positivity is of great help in setting up the most appropriate
management, but it does not give us the assurance that the
disease will be more severe, that the patients will develop
organ involvement or even that they will develop malig-
nancies. Because they are not specific tests for these
manifestations, their positivity should act as a clue that
draws our attention to such possible conditions. Their
superficial interpretation could lead to excessive and use-
less diagnostic procedures and over-treatment, also causing
unnecessary concern to the patient and his family.
UN-
DETECTABLE 
ADA
SUB 
THERAPEUTIC 
DRUG LEVEL
Repeat 
assessments. 
Pharmacodyna-
mic problem 
THERAPEUTIC 
DRUG LEVEL
Use drugs with 
other target 
than TNF-α
DETECTABLE 
ADA
SUB 
THERAPEUTIC 
DRUG LEVEL
Change to 
different anti-
TNF-α inhibitor
THERAPEUTIC 
DRUG LEVEL
Intensify the 
current tratment 
regimen
Fig. 3 Proposed algorithm in
patients with a rheumatic
disease and anti-TNF-a
treatment failure. Modified from
Steenholdt et al. [80]
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These data, therefore, must be evaluated critically and
integrated with the clinical history of the patient and with
other laboratory data resulting in an a priori probability of
having a specific disease. In an ancient Indian tale, sev-
eral blind men seek to learn the nature of an elephant.
One who examines the trunk describes the elephant to be
like a snake. Another who feels one of the powerful legs
states that the animal is similar to a tree trunk. The last,
having touched the large elephant’s ear, believes that this
animal might be able to fly. Each blind man, focusing
only on that part they were able to examine, missed
entirely the true shape of the elephant. Understanding the
individual components of the biological complexity of
subjects is an important first step, but to better appreciate
the ‘‘big picture,’’ avoiding the mistake of those blind
men is necessary to integrate all the information that
comes from the patient as a unique individual, different
from any other, so that the intent of personalized medi-
cine can be realized.
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